1. Home
  2. AVTX

as 08-22-2025 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Founded: 2011 Country:
United States
United States
Employees: N/A City: WAYNE
Market Cap: 118.6M IPO Year: 2015
Target Price: $31.00 AVG Volume (30 days): 335.9K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -6.01 EPS Growth: N/A
52 Week Low/High: $3.39 - $16.00 Next Earning Date: 08-07-2025
Revenue: $441,000 Revenue Growth: -45.35%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AVTX Daily Stock ML Predictions

Share on Social Networks: